Homology Medicines, Inc. Business Finance Contracts & Agreements
25 Contracts & Agreements
- Assignment Agreements (1 contract)
- Contribution Agreements (1)
- Investor Rights Agreements (2)
- Loan Agreements (8)
- Note Agreements (2)
- Purchase Agreements (3)
- Stock Agreements (5)
- Underwriting Agreements (3)
- Q32 Bio Inc. 2017 Stock Option and Grant Plan (Filed With SEC on December 18, 2023)
- Seventh Amendment to Loan and Security Agreement, dated November 2, 2023, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Sixth Amendment to Loan and Security Agreement, dated July12, 2023, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Fifth Amendment to Loan and Security Agreement, dated April 26, 2023, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Fourth Amendment to Loan and Security Agreement, dated December 21, 2022, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Third Amendment to Loan and Security Agreement, dated August 10, 2022, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Second Amendment to Loan and Security Agreement, dated June 30, 2022, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- First Amendment to Loan and Security Agreement, dated December 30, 2021, by and between Q32 Bio Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2023)
- Loan and Security Agreement, dated as of December 11, 2020, by and between Q32 Bio Inc. and Silicon Valley Bank, as amended (Filed With SEC on December 18, 2023)
- Amendment No. 1 to Note Purchase Agreement, dated May 20, 2022, by and between Q32 Bio Inc. and the individuals and entities party thereto (Filed With SEC on December 18, 2023)
- Note Purchase Agreement, dated May 20, 2022, by and between Q32 Bio Inc. and the individuals and entities party thereto (Filed With SEC on December 18, 2023)
- Asset Purchase Agreement, dated August 12, 2022, by and between Q32 Bio Inc. and Horizon Therapeutics Ireland DAC (Filed With SEC on December 18, 2023)
- Contribution Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Filed With SEC on March 23, 2022)
- Amendment No. 1 to Equity Securities Purchase Agreement dated as of January 28, 2022 by and among Homology Medicines, Inc., Roadrunner Solutions LLC, Oxford Biomedica (US), Inc.... (Filed With SEC on March 23, 2022)
- Equity Securities Purchase Agreement, dated January 28, 2022, by and among Homology Medicines, Inc., Roadrunner Solutions LLC, Oxford Biomedica (US), Inc. and, solely for purposes... (Filed With SEC on March 23, 2022)
- Assignment and Assumption Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Filed With SEC on March 23, 2022)
- Underwriting Agreement, dated April 6, 2021, by and between the Company and BTIG, LLC (Filed With SEC on April 9, 2021)
- Stock Purchase Agreement, dated November 9, 2020, by and between Homology Medicines, Inc. and Pfizer Inc (Filed With SEC on November 9, 2020)
- Amended and Restated Investors Rights Agreement, dated July 28, 2017, by and among Homology Medicines, Inc. and the investors named therein, as amended by Amendment No. 1 Amended... (Filed With SEC on November 9, 2020)
- Underwriting Agreement, dated April 9, 2019, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Cowen and Company, LLC, as representatives of the... (Filed With SEC on April 11, 2019)
- 2018 Employee Stock Purchase Plan Offering Document (Filed With SEC on November 13, 2018)
- 2018 Employee Stock Purchase Plan (Filed With SEC on March 19, 2018)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on March 19, 2018)
- Form of Underwriting Agreement (Filed With SEC on March 19, 2018)
- Amended and Restated Investors Rights Agreement dated July 28, 2017, among the Registrant and the investors named therein (Filed With SEC on March 2, 2018)
